A randomized controlled trial of lamivudine to treat acute hepatitis B
Open Access
- 22 December 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 45 (1), 97-101
- https://doi.org/10.1002/hep.21486
Abstract
The role of antivirals in patients with acute viral hepatitis B (AVH‐B) has not been evaluated in controlled trials. The aim of this study was to evaluate the efficacy of lamivudine in patients with AVH‐B. AVH‐B patients with serum bilirubin of more than 5 mg/dL were randomized to receive either 100 mg of lamivudine daily for 3 months (group 1, n = 31) or placebo (group 2, n = 40). Patients were considered to have severe AVH‐B if they fulfilled 2 of 3 criteria: (1) hepatic encephalopathy; (2) serum bilirubin ≥ 10.0 mg/dL; and (3) international normalized ratio (INR) ≥ 1.6. At week 4, HBV DNA levels were significantly lower (P = 0.037) in group 1 (median: 3.6721 log copies/mL) than group 2 (median: 4.2721 log copies/mL). Thereafter, HBV DNA levels were comparable in the 2 groups. The improvement in serum bilirubin, ALT, and INR values was similar in the 2 groups. Twenty‐two patients (71%) in group 1 and 25 patients (62.5%) in group 2 had severe AVH‐B. Results were similar when patients with severe AVH‐B were analyzed separately. After 12 and 18 months, 93.5% and 92.5%, respectively, of patients in the lamivudine group and 96.7% and 97.5%, respectively, of patients in the placebo group lost HBsAg. There were no deaths in either group. After 1 year, 21 patients (67.7%) in group 1 and 34 patients (85%) in group 2 developed protective anti‐HBs titers (P = 0.096). All HBeAg‐positive patients in both groups lost e antigen and anti‐HBe developed in 71% and 87.5% of patients in groups 1 and 2, respectively (P = 0.132). Conclusion: Though lamivudine causes a greater decrease in levels of HBV DNA, it does not cause significantly greater biochemical and clinical improvement as compared to placebo in patients with acute hepatitis B. HEPATOLOGY 2007;45:97–101.)Keywords
This publication has 13 references indexed in Scilit:
- Characterization of Naturally Occurring and Lamivudine-Induced Surface Gene Mutants of Hepatitis B Virus in Patients with Chronic Hepatitis B in IndiaIntervirology, 2006
- Lamivudine treatment for acute severe hepatitis B: a pilot studyLiver International, 2004
- Long-term histologic and virologic outcomes of acute self-limited hepatitis BHepatology, 2003
- Lamivudine in severe acute viral B hepatitisJournal of Hepatology, 2003
- Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantationLiver Transplantation, 2002
- Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B.Hepatology Research, 2002
- Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virusJournal of Medical Virology, 2002
- Lamivudine in the Treatment of Acute Hepatitis BNew England Journal of Medicine, 2000
- Lamivudine treatment for acute hepatitis B after liver transplantationJournal of Hepatology, 1998
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B InfectionNew England Journal of Medicine, 1995